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Abstract
Background Despite improvements in liver surgery over the
past decades, hemostasis during hepatic resections remains
challenging. This multicenter randomized study compares
the hemostatic effect of a collagen hemostat vs. a carrier-
bound fibrin sealant after hepatic resection.
Methods Patients scheduled for elective liver resection
were randomized intraoperatively to receive either the
collagen hemostat (COLL) or the carrier-bound fibrin
sealant (CBFS) for secondary hemostasis. The primary
endpoint was the proportion of patients with hemostasis
after 3 min. Secondary parameters were the proportions
of patients with hemostasis after 5 and 10 min, the total
time to hemostasis, and the complication rates during a
3 months follow-up period.
Results A total of 128 patients were included. In the COLL
group, 53 out of 61 patients (86.9 %) achieved complete
hemostasis within 3 min after application of the hemostat
compared to 52 out of 65 patients (80.0 %) in the CBFS
group. The 95 % confidence interval for this difference
[−6.0 %, 19.8 %] does not include the lower noninferiority
margin (−10%). Thus, the COLL treatment can be regarded as
noninferior to the comparator. The proportions of patients
with hemostasis after 3, 5, and 10 min were not significantly
different between the two study arms. Postoperative mortality
and morbidity were similar in both treatment groups.
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Conclusion The collagen hemostat is as effective as the
carrier-bound fibrin sealant in obtaining secondary hemostasis
during liver resection with a comparable complication rate.
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Introduction
Improvements in preoperative imaging, perioperative care and
surgical technique have led to expansion of hepatic surgery
during the last decades including extended hepatic resections
[1, 2]. Likewise, the number of hepatic resections has in-
creased [3, 4], while perioperative outcome has improved
[3–5]. Nonetheless, liver surgery is still associated with sub-
stantial mortality and morbidity rates even at high volume
centers [6]. In addition, the advent of neoadjuvant chemother-
apy, especially in patients with colorectal liver metastases [7],
demographic changes in Europe and the USAwith an increas-
ing number of elderly patients as well as the rising number of
liver resections in patients with impaired liver function have
increased the likelihood of complications in hepatic surgery.
Therefore, safe liver surgery remains challenging and a main
objective not only for surgeons and patients but also for health
care providers, since complications following liver surgery are
associated with substantial health care costs [8, 9].
A frequent contributor to intraoperative complications is
hemorrhage from the resection surface which occurs indepen-
dent of the resection technique and is frequently triggered by
impaired coagulation. Furthermore, hematoma as well as bile
leakage from the resection surface can lead to troublesome
postoperative complications. Therefore, rapid and effective
treatment of bleeding during and after hepatic surgery reduces
blood loss and may help to reduce perioperative complica-
tions. It subsequently may reduce the need for transfusion,
operative time, and duration of hospital stay.
In order to achieve control over parenchymal diffuse bleed-
ing and complications attributed to bleeding, various locally
applicable hemostatic agents are in use. These agents include
bone wax, gelatin, collagen, oxidized cellulose, fibrin sealants
glues, and synthetic glues [10, 11]. Some evidence from
randomized controlled trials (RCTs) exists regarding the
use of fibrin sealants on their own [12–14] or combined
with a carrier matrix [15–18]. However, the routine use
of fibrin sealants has to be judged against noticeable
additional costs. A combined product with well-
documented efficacy is Tachosil®. It consists of a colla-
gen patch carrying the fibrin glue components human
fibrinogen and human thrombin. It was shown in two
RCTs [16, 17] to be superior in obtaining intraoperative
hemostasis over argon plasma coagulation in liver resec-
tion by reducing the time to hemostasis significantly.
The collagen fleece Sangustop® is a novel means of
treating regional bleeding during surgical procedures. It is
made up of a mesh-like matrix of absorbable collagen fibrils
to ensure flexibility of the hemostat while at the same time
preserving tensile strength. The matrix allows for an increased
surface area to enhance the hemostatic effect. In contrast to the
carrier-bound fibrin sealant, it does not contain any pharma-
cologically active components. The objective of this random-
ized controlled multicenter trial was to assess if the collagen
hemostat Sangustop® is as effective as the carrier-bound fibrin




The study was designed as a prospective, noninferiority, mul-
ticenter, two-arm, randomized, single-blinded study. To show
transparency the protocol of the Efficacy and Safety of S-
angustop® as hemostatic agent vs. a CArrier-bound fibrin
sealant during LIVER resection (ESSCALIVER) study was
registered at http://www.clinicaltrials.gov (identifier:
NCT00918619), and the study protocol was published
previously [19]. Ethical approval was obtained from the
responsible ethics committees. The study was sponsored by
Aesculap AG (Tuttlingen, Germany). Clinical monitoring and
data management were contracted to Centrial GmbH
(Tübingen, Germany). Statistical planning and analysis was
performed by Dr. M. Koehler GmbH (Freiburg, Germany).
Participants
Only patients aged over 18 years scheduled for an elective,
open liver resection (segmental or nonsegmental) were eligi-
ble for participation in the study. Exclusion criteria were
presence or sequelae of coagulation disorders, medical history
or clinical evidence of liver cirrhosis, Klatskin tumor, partic-
ipation in another clinical study within the last 30 days, preg-
nancy or breast feeding, concurrent or previous therapy with
systemic pharmacologic agents promoting blood clotting (in-
cluding but not limited to tranexamic acid, activated factor
VII, and aprotinine), and known allergy or hypersensitivity to
human thrombin or to human fibrinogen or to riboflavin or to
proteins of bovine origin. Furthermore, a number of intraop-
erative exclusion criteria, evaluated immediately after liver
resection, had to be ruled out before intraoperative randomi-
zation could be carried out, namely, resection area estimated
by operating surgeon to be less than 16 cm2, an infected
wound area, and persistent major bleeding or no bleeding after
primary operative hemostatic procedures.
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Written informed consent was obtained from all eligible
patients during the screening visit.
Surgical technique and intervention
The liver surgery was performed according to the respective
center’s local standards. The only provisions were regarding
the dissection techniques and the primary hemostatic
methods. The following techniques of liver resection were
allowed: Cavitron Ultrasonic Surgical Aspirator (CUSA®),
Hydrojet®, clamp crushing, scissors, and stapler transection.
Any techniques of liver resection with a coagulation activity
were not permitted, e.g., argon plasma coagulation (APC),
Habib™-Sealer, Tissue Link®, and UltraCision®.
For achieving primary hemostasis, only sutures and vascu-
lar clips were permitted, and it was performed in accordance
with the preferences of the surgeon. If complete hemostasis
was achieved with these primary hemostatic measures (i.e., no
bleeding from the resection area), then the patient had to be
excluded from the trial. In case of persisting bleeding from the
resection area, adequate surface size patients were randomized
to either the COLL or the CBFS group.
COLL group
Sangustop® fleeces (Aesculap AG) measuring 5×8 cm were
applied to the bleeding resection area. Mild pressure was
applied using dry instruments until the collagen fleece adhered
to the resection surface. The resection area had to be covered
completely with the fleece, and an overlap of >1 cm was
mandatory in cases were more than one product was used.
Additional fleeces could be put on the site at any time during
the measurement phase if blood seeped through the fleece.
The fleeces remained in situ as they are bioabsorbable. Upon
application of the collagen hemostat to the resection surface, a
stopwatch was started and the bleeding site was inspected
every minute from the beginning until bleeding stopped, for
a maximum of 10 min.
CBFS group
Tachosil® (Nycomed, Linz, Austria) patches measuring 4.8×
9.5 cm were applied to the resection area after being moist-
ened with saline solution. The yellow-coated side of the patch
containing the active hemostatic components was applied
against the resection surface for a minimum of 3 min accord-
ing to the manufacturer’s instruction. After this period, hemo-
stasis was controlled for the first time, followed by inspections
after every minute until bleeding was stopped, but for a
maximum of 10 min. As for the COLL group, the resection
area had to be covered completely with a mandatory overlap
of >1 cm in cases where more than one patch was used.
Additional patches could be used at any time during the
measurement phase if blood seeped through the patch. The
patches remained in situ as they are bioabsorbable.
Hemostasis was defined as being achieved when there was
no visible bleeding from the target site, neither through nor
from the sides of the fleeces/patches. Evaluation was done by
the operating surgeon/investigator. If hemostasis was not
achieved within 10 min, other methods of hemostasis were
allowed in both groups. No specific treatment was defined and
all measures were allowed without restrictions.
After completion of the hepatectomy, a blot of the transec-
tion surface was made on a sheet of paper, and later on, this
area was calculated from weighing the cutout piece of the
surface area imprint. The results of the histopathology study
with regard to the nontumorous associated liver microstruc-
ture (e.g., presence of steatosis, fibrosis, etc.) and the transfu-
sion units given within the first week were recorded.
Outcomes
The objective of the ESSCALIVER trial was to show that the
COLL hemostat is noninferior to the CBFS in stopping bleed-
ing after liver resection. The primary endpoint was complete
hemostasis within 3 min after application of the hemostat. We
choose this endpoint because the CBFS has to be pressed to
the bleeding site for a minimum of 3 min according to the
manufacturer’s instruction. Hence, 3 min was the earliest time
point when hemostasis could be evaluated in both groups.
Secondary efficacy variables were the proportion of pa-
tients with hemostasis after 5 and 10 min as well as the time to
hemostasis. To assess safety, the complication rate was docu-
mented in both treatment groups until 3 months
postoperatively.
After 1 month (±5 days) and after 3 months (±10 days),
patients were phoned by the investigator or study assistant.
Using a predefined questionnaire, patients were asked open-
ended questions to evaluate whether he/she had experienced
any complications during the interim time interval.
Randomization
A 1:1 intraoperative randomization was performed using iden-
tical looking, sealed, and numbered opaque envelopes. Ran-
domization was stratified by study center. Lists with a block
size of 4 were generated for each participating center prior to
the initiation of the study using the Software RandList of the
DatInf GmbH (Tübingen, Germany). Envelopes had to be
opened in a sequential manner, after intraoperative inclusion
criteria were met by one of the participating investigators. The
eligible investigator who opened the randomization envelope
had to date and sign the randomization sheet. The sequence of
opening the envelopes was monitored regularly.
Langenbecks Arch Surg (2014) 399:725–733 727
Blinding
ESSCALIVER is a single-blinded trial, i.e., patients were not
informed about their assignment in order to increase reliability
of secondary outcomes, assessed during the follow-up visits.
Due to the appearance of the products used and the differences
in their application, blinding of the primary outcome assessor
was not possible. However, since randomization was per-
formed after the liver transection, the investigators performed
the transection, the primary hemostasis, and the assessment of
the intraoperative inclusion criteria without knowing which
hemostatic product was going to be tested.
Statistics
Primary variables
To show that COLL is noninferior to CBFS in regard to
hemostasis, the following noninferiority design was chosen.
Noninferiority was demonstrated if the lower limit of the
observed two-sided 95 % confidence interval of the observed
d i f f e r ence in p ropo r t i on s o f t r e a tmen t a rm 1
(COLL)−treatment arm 2 (CBFS) does not fall below
−0.100. The analysis was based on the per protocol population
and repeated for the intent-to-treat population, since in a
noninferiority trial use of the per protocol analysis set is
generally seen as the conservative approach. If the 95 %
confidence interval for the treatment effect not only lies en-
tirely above –0.1 but also above zero, then there is evidence of
superiority in terms of statistical significance at the 5 % level.
The difference in proportions between the two treatment arms
(treatment arm 1 vs. treatment arm 2) was tested with a
Fisher’s exact test to reject the null hypothesis of no
difference.
Secondary variables
The proportion of patients with hemostasis 5 and 10 min after
application was reported descriptively based on the intent-to-
treat population as well as the per protocol population. This
includes the proportions, the estimated difference in propor-
tions, and the associated 95 % confidence intervals. Differ-
ences in time to hemostasis were tested with a log–rank test at
the 5 % alpha level. Kaplan–Meier curves were displayed,
with median estimates and confidence limits provided. The
analyses were based on the intent-to-treat population and
repeated for the per protocol population. Adverse events
(AEs) were summarized and categorized by severity (mild,
moderate, and severe), seriousness (serious or nonserious),
and relationship to device (certain, probable, possible, unlike-
ly, and not assessable).
Sample size
The sample size was calculated to test for noninferiority of the
control group vs. the experimental group in terms of hemo-
stasis 3 min after application of the hemostatic product. In a
previous study the proportion of patients with complete he-
mostasis after 3 min was estimated to be 73 % for the control
[17]. With 60 subjects in each group, the lower limit of the
observed one-sided 97.5 % confidence interval will be expect-
ed to exceed −0.100 with 93 % power when the proportion of
the treatment arm 2 (CBFS) is 0.730 and the expected pro-
portion of the treatment arm 1 (COLL) is 0.880. Results are
based on 100 simulations using the Newcombe–Wilson score
method to construct the confidence interval. Assuming a drop-
out rate of 5 %, a total number of 126 patients are needed to be
enrolled. The expected difference of 15 % was justified by
preclinical data [20].
Results
A total of 137 patients consented to participate between Jan-
uary 2010 and October 2010. Of those, 128 patients were
available for intraoperative randomization. Reasons for drop-
out before randomization were: dry resection area (4),
irresectable tumor (3), resection area too small (1), and con-
sent withdrawn (1). One patient was excluded because be-
tween intraoperative randomization and the application of the
hemostats, the resection area was found to be dry. Thus, 127
patients (COLL: n=62 and CBFS: n=65) received a study
intervention and were available for evaluation. In one patient,
the investigational product COLL was applied wet instead of
dry. This represented improper use of the product and the
patient had to be removed from the per protocol analysis.
Patients were recruited in eight study centers (6 to 32
patients per center). The CONSORT-type diagram (Fig. 1)
shows the flow of participants through each stage of the study.
The two study groups were comparable for all patients and
procedural characteristics. Demographics and laboratory data
at baseline are shown in Table 1. The data recorded during the
surgical procedure are summarized in Table 2. The results of
the histopathological examination on nontumorous liver mi-
crostructure is shown in Table 1. In the COLL group, 53 out of
61 patients (86.9 %) reached hemostasis 3 min after applica-
tion of the product compared to 52 out of 65 patients (80.0 %)
in the CBFS group. The 95 % confidence interval for the
difference of 6.9 % was [−6.0 %, 19.8 %]. Since the lower
limit was above −10 %, the COLL treatment is regarded as
clinically noninferior to the comparator CBFS treatment. In
addition a statistical comparison of the devices was performed
using Fisher’s exact test. The two-sided test showed a p value
of 0.3453.
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The proportion of patients with hemostasis 5 min after
application of the hemostatic products was 93% for the COLL
group and 95 % in the CBFS group, CI 95 % [−10.0 %,
6.1 %]; p=0.7114. In one patient treated with COLL, hemo-
stasis was not achieved after 10 min and additional sutures
were applied after that time. In the CBFS arm, hemostasis was
achieved in all patients within 10 min. In total, 98 % of
patients receiving the COLL hemostat and 100 % of patients
treated with CBFS obtained hemostasis within 10 min, with
CI 95 % [−4.8 %, 1.6 %]. The mean time to hemostasis was
calculated to be 2.2 (SD±1.60)min for the COLL arm and
3.38 (SD±0.88)min for the CBFS arm. Note that due to the
different mode of application, the time measurement started at
time 0 min in the COLL arm and at 3 min for the CBFS arm.
Thus, the two cannot be compared with each other within the
first 3 min. The Kaplan–Meyer curves are shown in Fig. 2.
The repeat of the analysis of primary and secondary efficacy
variables using the ITT population showed similar results and
confirmed the finding of the noninferiority of the COLL
treatment vs. the comparator CBFS.
A total of 152 COLL fleeces were used in 62 patients
(mean 2.45; minimum one piece and maximum seven pieces
per patient). A total of 151 CBFS patches were applied in 62
patients (mean 2.32; minimum one piece and maximum four
pieces per patient). The calculated use of products per cm2
resection area was similar in both treatment groups (COLL:
0.04±0.022 and CBFS: 0.03±0.016; p=0.8263). The blood
parameters were tested on the first postoperative day. They
were within the normal values and did not differ between the
two treatment groups. Blood transfusions were necessary in
20 COLL patients (33 %) and in 19 CBFS patients (29 %)
during the first postoperative week.
Safety analysis
Four patients died during the course of the study resulting in
an overall 3-month mortality of 3.2 %: one patient in the
COLL group (heart failure 8 days after surgery) and three
patients in the CBFS group (myocardial infarction 14 days
after surgery; multiorgan failure 41 days after surgery;
multiorgan failure 28 days after surgery). None of the deaths
was associated with the hemostatic agents. Furthermore, no
hemostat-related adverse event was reported. Overall, 267
adverse events (AEs) were reported in 77 patients during the
course of the study (121AEs in 38 patients in the COLL group
and 146 AEs in 39 patients in the CBFS group; Table 3). The
most common AEs were anemia, constipation, and abdominal
pain. A total of 21 complications were rated as serious in 16
patients (26 %) in the COLL group, whereas 29 serious
complications occurred in 23 patients (35 %) in the CBFS
group. The majority of serious complications were related to
the surgical procedure, the underlying disease, or the preop-
erative health status. The most frequent serious surgical com-





Excluded n = 9
Dry resection area n = 4
Irresectable tumor n = 3
Small resection area n = 1
Consent withdrawn n = 1
Allocated to COLL n = 63
Received intervention n = 62
Did not receive intervention n = 1
dry resection area n = 1
Allocated to CBFS n = 65
Received intervention n = 65
Did not receive intervention n = 0
Lost to follow-up n = 1
Deaths n = 1
Lost to follow-up n = 3
Deaths n = 3
Analysed n = 61
Excluded from analysis n = 1
Protocol violation  n = 1
Analysed n = 65




















Fig. 1 CONSORT flow chart
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bile leaks (3.2 % in COLL and 3.1 % in CBFS),
intraabdominal fluid collection (3.2 % in COLL and 3.1 %
in CBFS), and wound infection or dehiscence (1.6% in COLL
and 4.6 % in CBFS; Table S4). There were no unplanned
reoperations in our study, but one patient in the COLL group
underwent planned relaparotomy within the study period for
complete tumor resection.
Discussion
Hemostasis in hepatic surgery is of considerable clinical sig-
nificance due to the high number of liver resections performed
each year, the significant morbidity and mortality [3, 4]) as
well as the substantial health care costs [21] associated with
intraoperative or postoperative hemorrhage in liver surgery.
Furthermore, inadequate hemostasis during hepatectomy is
associated with the unfavorable need for blood transfusion
[22], postoperative complications [23, 24], increased opera-
tive time, and early tumor recurrence [25]. At the resection
margins larger vessels and bile ducts are either clipped or
ligated with sutures. However, parenchymal bleeding can still
persist. Other methods for controlling this secondary bleeding
are available, including fibrin glue, patches containing coag-
ulation factors as well as collagen and cellulose based mate-
rials. In the current multicenter, randomized, controlled trial,
we compared the efficacy and safety of a collagen fleece
COLL without coagulation factors to a carrier-bound fibrin
sealant CBFS for secondary hemostasis in elective open liver
resections.
The study population was recruited from patients referred
to the study centers for elective liver surgery. By applying
wide inclusion and exclusion criteria, the Esscaliver trial
aimed to reflect everyday clinical practice and intended to
increase generalizability. Furthermore, since neither the surgi-
cal resection procedure nor resection instruments were stan-
dardized with few exceptions (markedly a minimum resection
surface of 16 cm2 and the avoidance of argon plasma coagu-
lation for primary hemostasis), the results of the trial seem to
be applicable to wide range of hepatectomy procedures, indi-
cations, and surgeons.
Table 1 Patient demographics
COLL (n=62) CBFS (n=65)
Demographics
Male, n (percent) 34 (55 %) 40 (62 %)
Mean age years, mean (SD) 61.0 (12.8) 61.9 (13.2)
Body mass index, mean (SD) 26.6 (4.2) 28.1 (14.3)
ASA status
P1, n (percent) 13 (21 %) 9 (14 %)
P2 31 (50 %) 33 (51 %)
P3 18 (29 %) 23 (35 %)
Preoperative chemotherapy 21 (34 %) 24 (37 %)
Underlying diagnosis
Liver metastasis 38 (61 %) 42 (65 %)
Hepatocellular carcinoma 5 (8 %) 11 (17 %)
Adenoma of the liver 3 (5 %) 3 (5 %)
Cholangiocellular carcinoma 2 (3 %) 3 (5 %)
Gall bladder carcinoma 4 (6 %) 1 (2 %)
Hemangioma 2 (3 %) 2 (3 %)
Carcinoma of unknown primary
origin
2 (3 %) 2 (3 %)
Focal nodular hyperplasia (FNH) 1 (2 %) –
Neuroendocrine tumor (NET) 1 (2 %) –
Others 4 (6 %) 1 (2 %)
Histopathology
Steatosis 18 (29 %) 17 (26 %)
Fibrosis 13 (21 %) 14 (22 %)




1.023 (0.1034) 1.020 (0.0937)
Partial thromboplastin time
in second, mean (SD)
31.16 (4.724) 30.80 (5.930)
Hemoglobin in gram per deciliter,
mean (SD)
13.12 (1.639) 13.60 (1.436)
Hematocrit in percent, mean (SD) 39.36 (3.981) 40.51 (3.667)





Techniques of liver resection
CUSA® 37 (60 %) 37 (57 %)
Scissors 22 (35 %) 19 (29 %)
Clamp crushing 13 (21 %) 15 (23 %)
Stapler 9 (15 %) 14 (22 %)
Hydrojet® 1 (2 %) 1 (2 %)
Method of primary hemostasis
Sutures 57 (92 %) 58 (89 %)
Clips 51 (82 %) 52 (80 %)
Resection
Segmental 43 (72 %) 51 (80 %)
Nonsegmental 17 (28 %) 13 (20 %)
Segmental and nonsegmental 2 (3 %) 1 (2 %)
Weight of resected liver in grams, mean (SD) 414 (357) 386 (302)
Resection area in square centimeters, mean (SD)
Estimated by surgeon 81 (65) 66 (42)
Measured from blot 83 (51) 79 (41)
Central venous pressure in millimeters of
mercury, mean (SD)
6.7 (4.8) 5.9 (4.9)
Pringle yes, n (percent) 24 (39 %) 28 (43 %)
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Our results allow the conclusion that, given the predefined
margins of noninferiority, the collagen hemostatic fleece can
be regarded as noninferior to the comparator carrier-bound
fibrin sealant in achieving secondary hemostasis in liver re-
sections. Both treatment options were highly effective with
86.9 % of patients in the COLL arm and in 80.0 % of patients
in the CBFS arm achieving complete hemostasis after 3 min.
Furthermore, after 5 min and after 10 min, hemostasis was
achieved in all but one patient, underlining the efficacy of both
COLL and CBFS. The median time to hemostasis was re-
duced by about 1 min after the application of COLL (2.2 min)
in comparison to CBFS (3.4 min). This difference is not
necessarily due to a different hemostatic efficacy. It might also
reflect specificities in trial design. The CBFS needs to be
applied for a minimum of 3 min according to the manufac-
turer’s instruction, while the same limitation does not exist for
COLL. Evaluation for complete hemostasis was censored till
this time point for the CBFS but not the COLL group.
The validity of our results is underlined by comparing our
data to previous trials that have employed a carrier-bound
fibrin sealant and have found similar median hemostatic times.
Fischer at al. [16] reported a median hemostatic time of
3.6 min and Frilling et al. [17] a median time of 3.9 min. This
is very close to the reported 3.4 min observed in this trial. We
could rule out the possibility that the equivalent hemostatic
effect was due to an increase use of COLL as the mean
number of fleeces/patches used per area was similar in both
treatment arms.
In our study, the safety profile of both treatments seems to
be comparable, evidenced by the almost identical percentage
of patients experiencing an adverse event in both study arms,
as well as the distribution of the most frequent adverse events.
Furthermore, the number and frequency of patients requiring
blood or blood components transfusions within the first post-
operative week was very similar in both treatment arms indi-
cating that there is no difference with regard to postoperative
bleeding complications.
We rule out the possibility of a random effect on our results
since the studies’ baseline characteristics such as age, gender,
BMI, ASA status, baseline blood values, and indication for
liver resection were well balanced. In addition, the intraoper-
ative data regarding surgical technique and histopathological
findings of nontumorous liver tissue were evenly distributed
over the two study arms indicating that the randomization
process was effective in producing comparable study groups
differing only in the way of secondary hemostatic treatment.
A clear limitation of our trial was the restriction to high-
volume surgical centers with high expertise in liver surgery,
which might limit generalizability of the results. Furthermore,
the single-blinded trial design with the inability to blind the
primary outcome assessor was a limitation that might poten-
tially bias the results of our trial. We have tried to minimize
this effect by implementing an intraoperative randomization
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Fig. 2 Kaplan–Meier curves for
the time to hemostasis for COLL
(dashed line) and CBFS
Table 3 Adverse events
COLL (n=62) CBFS (n=65)
Total number of adverse events 121 146
Patients with at least one adverse event 38 (61.3 %) 39 (60.0 %)
Adverse events with an occurrence of >5 %
Anemia 14 (22.6 %) 14 (21.5 %)
Constipation 7 (11.3 %) 7 (10.8 %)
Abdominal pain 5 (8.1 %) 6 (9.2 %)
Nausea 5 (8.1 %) 6 (9.2 %)
Seroma 3 (4.8 %) 4 (6.2 %)
Thrombocytopenia 4 (6.5 %) 3 (4.6 %)
Hypokalemia 4 (6.5 %) 3 (4.6 %)
Vomiting 4 (6.5 %) 2 (3.1 %)
Wound infection 2 (3.2 %) 4 (6.2 %)
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resection, and primary hemostasis) have taken place. Another
limitation could be that the measurement of the time to hemo-
stasis is a subjective assessment and prone to bias. However,
currently, there seems to be no better method available, which
is reflected by the fact that it is the method of choice in
comparable studies [26, 27]. Furthermore, it is accepted by
the FDA as a primary endpoint for pivotal studies of fibrin
sealants [28].
Some other properties of the COLL have not been investi-
gated specifically in this study but should be mentioned.
Handling of the COLL is equivalent to the CBFS with one
marked difference: the COLL fleece does not need a
presoaking and can be used directly without activation, and
thus, it can be applied laparoscopically too. The COLL fleece
is absorbed more rapidly than the CBFS system (within
3 weeks vs. 12 weeks). Finally, although we did not perform
a cost effectiveness analysis in our trial, increasing the options
of effective hemostatic agents with comparable safety profile
allows to consider economic aspects in the choice of
hemostats.
Conclusion
In summary, this controlled multicenter randomized study
comparing a novel collagen hemostyptic fleece to an
established carrier-bound fibrin sealant revealed the noninfe-
riority of the collagen fleece in hepatic surgery. The results of
this study increase the available options for surgeons and
allows them to make choices based on surgical sites, handling
characteristics, or cost-effectiveness.
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